These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 37205107

  • 1. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y, Wang W, Wang F.
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores.
    Chen W, Cao K, Zhang L, Zhao X, Chen B, Li W, Shang R, Sun L, Jiang Z, Wang J, Xue W.
    Front Immunol; 2024; 15():1414753. PubMed ID: 39050848
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q, Zhang X, Huang M, Dai X, Gao J, Li S, Sheng L, Huang K, Wang J, Liu L.
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [Abstract] [Full Text] [Related]

  • 6. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
    Li D, Tang L, Hu J, Cao X, He Y.
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
    [Abstract] [Full Text] [Related]

  • 7. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
    Wu HX, Pan YQ, He Y, Wang ZX, Guan WL, Chen YX, Yao YC, Shao NY, Xu RH, Wang F.
    J Clin Oncol; 2023 Mar 20; 41(9):1735-1746. PubMed ID: 36473145
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
    Li ZC, Sun YT, Lai MY, Zhou YX, Qiu MZ.
    Int Immunopharmacol; 2022 Aug 20; 109():108790. PubMed ID: 35504202
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.
    Leone AG, Petrelli F, Ghidini A, Raimondi A, Smyth EC, Pietrantonio F.
    ESMO Open; 2022 Feb 20; 7(1):100380. PubMed ID: 35093742
    [Abstract] [Full Text] [Related]

  • 14. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, Smyth EC, Soon YY, Sundar R.
    J Clin Oncol; 2022 Feb 01; 40(4):392-402. PubMed ID: 34860570
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety Profile of PD-1 Inhibitors Versus Chemotherapy in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jin Z, Zhao M.
    J Immunother; 2023 Sep 01; 46(7):262-270. PubMed ID: 37338278
    [Abstract] [Full Text] [Related]

  • 16. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, Shariat SF, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).
    Eur J Cancer; 2021 Jul 01; 151():35-48. PubMed ID: 33962359
    [Abstract] [Full Text] [Related]

  • 17. Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Wang Y, Lau W, Li Y, Tian Y, Lei Y, Wang J, Xia F.
    Int J Surg; 2023 Nov 01; 109(11):3590-3601. PubMed ID: 37598406
    [Abstract] [Full Text] [Related]

  • 18. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N, Boyne DJ, Cheung WY, Cash SB, Arora P.
    JAMA Netw Open; 2021 Jan 04; 4(1):e2034201. PubMed ID: 33496794
    [Abstract] [Full Text] [Related]

  • 19. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
    Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, Prokop LJ, Moehler M, Kang YK, Shi Q, Ajani JA.
    JAMA Oncol; 2022 Oct 01; 8(10):1456-1465. PubMed ID: 36006624
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and adverse reactions analysis of PD-1/PD-L1 inhibitors in advanced esophageal squamous cell carcinoma.
    Wang LL, Xie YX, Liu Y.
    Eur Rev Med Pharmacol Sci; 2024 Jan 01; 28(2):659-667. PubMed ID: 38305608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.